



Effect of Aminaphtone on in vitro vascular permeability and capillary-like maintenance

Journal:	<i>Phlebology</i>
Manuscript ID	PHLEB-17-090.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	27-Aug-2017
Complete List of Authors:	Felice, Francesca; Laboratorio di ricerca cardiovascolare, dip Cardiotoracico e vascolare - Università di Pisa Belardinelli, Ester; University of Pisa, Cardiovascular Research Laboratory, Department of Surgical Medical and Molecular Pathology and Critic Area Frullini, Alessandro; studio medico flebologico, Santoni, Tatiana; University of Pisa, Department of Surgical Medical and Molecular Pathology and Critic Area Imbalzano, Egidio; Università degli Studi di Messina, Department of Clinical and Experimental Medicine Di Stefano, Rossella; U.O. angiologia universitaria, Dip Cardiotoracico e Vascolare - Università di Pisa
Revised Keywords:	Chronic venous insufficiency, Pharmacologic agents

1
2
3
4
5 **Effect of Aminaphtone on *in vitro* vascular permeability and capillary-like**
6
7 **maintenance**
8
9

10
11 Francesca Felice ^{a,*}, Ester Belardinelli ^a, Alessandro Frullini ^b, Tatiana Santoni ^a, Egidio
12
13 Imbalzano ^c, Rossella Di Stefano ^a
14
15

16
17
18 ^a Cardiovascular Research Laboratory, Department of Surgical Medical and Molecular
19
20 Pathology and Critic Area, University of Pisa, Via Paradisa, 2 - 56100 Pisa, Italy
21

22
23 ^b Studio medico flebologico, Figline Valdarno, Florence, Italy
24

25
26 ^c Department of Clinical and Experimental Medicine, University of Messina, Via
27
28 Consolare Valeria, Gazzi, 98125 Messina, Italy.
29

30
31
32
33
34
35
36 *Corresponding author:

37
38 Francesca Felice, Cardiovascular Research Laboratory, Department of Surgical Medical
39
40 and Molecular Pathology and Critic Area, University of Pisa, Via Paradisa, 2 - 56100
41

42
43 Pisa, Italy
44

45 Email: francesca.felice77@hotmail.it
46

47 Phone: +39 050 995836
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Aminaphtone (AMNA), a naphthoquinone used in the treatment of capillary disorders, may affect oedema in chronic venous insufficiency (CVI). Aim of study is to investigate the effect of AMNA on vascular endothelial permeability *in vitro* and its effects on three-dimensional capillary-like structures formed by Human Umbilical Vein Endothelial Cells (HUVECs).

HUVECs were treated with 50 ng/ml VEGF for 2h and AMNA for 6h. Permeability assay, VE-cadherin expression and Matrigel assay were performed.

VEGF-induced permeability was significantly decreased by AMNA in a range concentration of 1-20 $\mu\text{g/ml}$. AMNA restored VE-cadherin expression. Finally, 6h pre-treatment with AMNA significantly preserved capillary-like structures formed by HUVECs on Matrigel up to 48 h compared to untreated cells.

AMNA significantly protects endothelium permeability and stabilises endothelial cells organised in capillary-like structures, modulating VE-cadherin expression. These data might explain the clinical benefit of AMNA on CVI.

Keywords. Aminaphtone, Human Umbilical Vein Endothelial Cells, permeability, chronic venous insufficiency, capillary fragility, VE-cadherin

1. Introduction

Vascular permeability is an extremely complicated process that is affected by many different variables ¹. A rapid increase in vascular permeability occurs when the microvasculature is exposed to any of a number of vascular permeabilising factors, e.g. vascular endothelial growth factor A (VEGF-A), histamine, platelet activating factor ¹. This process has been implicated in many pathological conditions such as angiogenesis, ischaemic heart disease, acute and chronic inflammation, trauma, wound-healing ². The dynamic equilibrium between cell adhesion and cytoskeleton contraction plays an important role in maintaining the normal function of endothelial permeability ³. The intercellular junctions of endothelial cells have an important barrier function regulating the permeability to small molecules and even to cells ⁴. Several families of cytoadhesive proteins, such as the selectins, members of the immunoglobulin (Ig) superfamily, and cadherins, play major roles in mediating cell–cell interactions and therefore are candidates for receptors involved in capillary tube formation ⁵. Endothelial cells express both VE-(vascular endothelial) and N-(neuronal) cadherins. Whereas VE-cadherin is localised at sites of cell-cell contact, N-cadherin is distributed diffusely over the cell surface and does not seem to contribute to cell-cell adhesion ⁶. VE-cadherin and N-cadherin have been shown to participate in capillary tube formation. In particular, antibodies directed against VE-cadherin, but not against N-cadherin, PECAM-1 (Ig superfamily) or $\alpha_v\beta_3$ integrin, markedly inhibited the generation of capillary tubes ^{7,8}. Moreover, it has been demonstrated that blocking VE-cadherin

1
2
3
4
5 function leads to a marked reorganisation of the actin cytoskeleton, increased monolayer
6 permeability and enhanced neutrophil transmigration ^{7,9}.

9
10 Phlebotonics are known as venoactive drugs, whose mechanism of action is not well
11 established despite the availability of numerous studies concerning their
12 pharmacological and clinical properties. Phlebotonics **may have beneficial effects on**
13 **oedema and on some signs and symptoms related to CVI such as trophic disorders,**
14 **cramps, restless legs, swelling and paraesthesia when compared with placebo** ¹⁰.

16
17 Aminaphtone (C₁₈H₁₅NO₄, AMNA), a naphthohydrochinone used in the treatment of
18 capillary disorders, has been reported to be effective in reducing vessel permeability and
19 the healing of leg ulcers in patients with CVI **and other pathological conditions** ^{11,12}.

21
22 **In particular, in patients with idiopathic cyclic oedema syndrome, a clinical**
23 **conditions that exhibits a vascular capillary hyperpermeability accompanied by**
24 **oedema caused by the interstitial retention of fluid, a significant reduction in limb**
25 **size was obtained after treatment with AMNA (P<0.0001)** ¹². AMNA acts on
26 **venous, capillary and lymphatic levels, reducing hyperpermeability, increasing**
27 **venous resistance, and regulating lymphatic flux. This mechanisms of action result**
28 **in reduced venous stasis, improved venous return, and, therefore, inducing tissues**
29 **protection against toxins and free radicals, as demonstrated in a work of De Anna**
30 **et al. in patients with chronic venous and lymphatic stasis** ¹¹. Finally, the use of
31 **AMNA was associated with significant improvements in quality of life compared**
32 **with placebo in CVI patients** ¹³.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Aim of the present study is to investigate the effect of AMNA on *in vitro* model of
6
7 vascular endothelial permeability and to evaluate if the drug is able to stabilise
8
9 capillary-like structures formed by HUVECs in an extracellular matrix model.
10
11

12 13 14 **2. Materials and methods**

15 16 17 18 **2.1. Aminaphtone**

19
20 AMNA was generously gifted by Baldacci Spa, Pisa, Italy. Lyophilised AMNA 0.1 g
21
22 was diluted with dimethyl sulphoxide to obtain a 100 mg/ml concentration. The solution
23
24 was then diluted with Medium 199 (Lonza, Basel, Switzerland) supplemented with 1 %
25
26 foetal bovine serum (FBS; Hyclone, South Logan, UT, USA), penicillin/streptomycin,
27
28 HEPES (Lonza, Basel, Switzerland), glutamine (Sigma-Aldrich 3050 Spruce St., St.
29
30 Louis, Missouri 63103 United States), heparin (Epsoclar) and bovine retina-derived
31
32 extract as a complete growth medium.
33
34
35
36
37
38

39 **2.2. Cell isolation and culture**

40
41 HUVECs were isolated from fresh human umbilical cords by incubation with
42
43 collagenase, (Invitrogen, Auckland, New Zealand) and cultured on gelatine-coated
44
45 flasks in Medium199 (Lonza) containing 20% heat-inactivated FBS (Hyclone), sodium
46
47 heparin (Epsoclar), penicillin/streptomycin (Lonza), HEPES (Lonza), glutamine
48
49 (Sigma-Aldrich 3050 Spruce St., St. Louis, Missouri 63103 United States) and bovine
50
51 retina-derived extract in humidified atmosphere (37 °C, 5% CO₂). The P4–P5 cultures
52
53
54
55
56
57
58
59
60

1
2
3
4
5 were cultivated until sub-confluence was reached. Thereafter, HUVECs were exposed
6
7 to the different experimental conditions.
8
9

10 11 **2.3. Cell viability**

12 HUVECs, 3×10^4 cells/well, were seeded in 96-well plates in complete growth medium.
13
14 After 72 h, cells were washed with PBS and treated for 6 h with different concentrations
15
16 of AMNA (0 – 1 – 5 – 10 – 30 – 50 – 70 – 100 $\mu\text{g/ml}$) in growth medium containing 1%
17
18 FBS. After treatment, cells were washed twice with phosphate buffer saline (PBS) and
19
20 viability was evaluated by WST-1 assay. WST-1 assay is a colorimetric assay based on
21
22 the cleavage of tetrazolium salt (WST-1, 4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-
23
24 tetrazolium]-1,3-benzene disulphonate, Roche Applied Science, Mannheim, Germany)
25
26 by mitochondrial dehydrogenases in viable cells. Briefly, after treatment, HUVECs
27
28 were incubated with tetrazolium salt (10 $\mu\text{l/well}$) for 4 h at 37 °C, 5% CO₂. Then, the
29
30 formazan dye formed was quantified by measuring the optical density at 450 nm
31
32 (reference wavelength: 650 nm), by a multiplate reader (Titertek). The absorbance
33
34 directly correlated to the number of metabolically active cells. Viability was expressed
35
36 as percent of viable cells, calculated from the ratio of absorbance after treatment to
37
38 mean absorbance for the untreated control.
39
40
41
42
43
44
45
46

47 **2.4. Vascular permeability assay**

48 Vascular permeability was performed by Millipore assay kit (EMD Millipore
49
50 Corporation Division Headquarters, Massachusetts, USA) according to the manufacture
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 protocol. Briefly, 80% confluent HUVECs, were detached and plated on inserts (3×10^4
6
7 cells/insert) and incubated for 72 h at 37 °C, 5% CO₂, up to form a monolayer. Cells
8
9 were then washed and treated with different concentrations of AMNA (0.5-1-5-10-20
10
11 µg/ml) for 6 h with or without 50 ng/ml VEGF (Recombinant Human VEGF₁₆₅,
12
13 Peprotech EC Ltd, London, UK) for 2 h, in growth medium with 1% FBS. At the end of
14
15 incubation, all treatments were removed and an high molecular weight fluorescein
16
17 isothiocyanate-dextran (FITC-dextran, MW 70KDa) was used to evaluate permeability.
18
19 Plate was incubated in the dark for 20 min at room temperature. Permeation was
20
21 arrested by removing the inserts from the wells. The levels of FITC-dextran was
22
23 recorded by a sensitive fluorescence plate reader (Fluoroskan, Thermo Fisher ®), (Ex:
24
25 485 nm; Em: 538). The amount of diffused dextran has determined using calibration
26
27 curves established just with the stock solution.
28
29
30
31
32
33

34 **2.5. Western blot analysis of VE-cadherin**

35
36 To determine VE-cadherin and VE-cadherin phosphorylation expression, HUVECs
37
38 were seeded in appropriated density in 6 multiwells and cultured in complete growth
39
40 medium until confluence. Cells were afterwards washed and pre-treated with 10 µg/ml
41
42 AMNA for 6 h and then with 50 ng/ml VEGF for 2 h in medium with 1 % FBS. At the
43
44 end of each treatment cells were lysed at 4°C for 1 h in lysis buffer (50 mM Tris-HCl
45
46 pH 7.4, 150 mM NaCl, 1 mM PMSF, 1mM EDTA, 5 mg/ml Aprotinin, 5 mg/ml
47
48 Leupeptin, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS) and centrifuged at
49
50 10,000 X g for 15 min. The protein content of the supernatants was measured by
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Bradford method. Aliquots containing 50 mg of cell lysate proteins were subjected to
6
7 7.5% SDS-PAGE under reducing conditions and blotted onto nitrocellulose membrane
8
9 filters. The blots were blocked for 2 h at 37 °C in 2% BSA, 1mM Na₂HPO₄, 1.7mM
10 NaH₂PO₄, 150mM NaCl, 0.05 Tween-20 (PBS-T). The nitrocellulose membranes were
11
12 washed once with PBS-T for 15 min, three times for 5 min with 1mM PBS and
13
14 immunoblotted for 2 h at room temperature with rabbit polyclonal anti-VE Cadherin
15
16 (phospho Y685) antibody (Abcam Ltd) or with rabbit monoclonal anti-VE-cadherin
17
18 antibody (Cell Signaling Technology, Boston, USA). After one washing with PBS-T
19
20 and three washing with PBS, the blots were incubated for 1 h at room temperature with
21
22 HRP labelled anti-rabbit IgG, washed with PBS, developed for 2 min with ECL reagent
23
24 (Pierce) and exposed to Biomax film (Kodak Co.). The densitometry data of the protein
25
26 bands were obtained using ImageJ software, and the objective protein expression was
27
28 evaluated by the densitometry ratio of the objective proteins to β-actin.
29
30
31
32
33
34
35

36 **2.6. Immunofluorescent detection of VE-cadherin**

37
38 The distribution of VE-cadherin in HUVEC monolayers was assessed by
39
40 immunofluorescent techniques using previously described procedure¹⁴ with
41
42 modifications. Cells were placed on multiwell slides. Confluent cultures of HUVECs
43
44 were pre-treated with AMNA (10 µg/ml) for 6 h and with VEGF (50 ng/ml) for 2 h in
45
46 medium with 1 % FBS. At the end of treatment, cells were washed three times with
47
48 PBS containing 1 mM CaCl₂ and 1 mM MgCl₂ (DPBS) and then fixed with 4%
49
50 formaldehyde at room temperature for 15 min. The formaldehyde was then aspirated
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 and the cells were washed three times with DPBS. The washed cells were then
6
7 permeabilised with 0.5% Triton X-100 for 5 min at room temperature. Non-specific
8
9 binding sites were blocked by incubation with 3% BSA in DPBS for 5 min at room
10
11 temperature. The BSA was then aspirated and the cells were immediately incubated
12
13 with primary mouse monoclonal antibodies against human VE-cadherin (10 mg/ml in
14
15 DPBS) (Cell Signaling Technology, Boston, USA) for 1 to 12 h at 37°C in a humidified
16
17 chamber. At the end of incubation the primary antibody were removed, cells were
18
19 washed three times and incubated at 37°C for 30 min with FITC- conjugated anti-mouse
20
21 secondary antibody (Cell Signaling Technology) diluted 1:200 and rhodamine-
22
23 phalloidin for F-actin staining (Cytoskeleton, Inc.) diluted 1:400 in DPBS. The chamber
24
25 slides were then washed and mounted with Vectashield mounting medium containing
26
27 DAPI (Vector Laboratories, UK). Slides were viewed under a fluorescence microscope
28
29 (Nikon) equipped with a digital CCD camera and 20X objective. Images were recorded
30
31 using AxioVision (Carl Zeiss MicroImaging, GmbH) software.
32
33
34
35
36
37

38 **2.7. *In vitro* capillary tube maintenance**

39
40 To evaluate the capability of AMNA to maintain capillary tubes formation, HUVECs
41
42 were treated with 10 µg/ml AMNA for 6h and then 7×10^4 cells/well were plated on
43
44 Matrigel (BD Biosciences) for 48 h. Matrigel was thawed on ice at 4 °C and used to
45
46 coat 24-well plates for 30 min at 37 °C. Cells were monitored and optical microscopy
47
48 images were captured at 2, 8, 24 and 48 h. Five independent images were taken for each
49
50 well.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 To quantify angiogenic structures formed by HUVECs, computational morphometric
6 analysis was performed ¹⁰. Briefly, representative fields from each experimental setting
7 were taken. Number of meshes (number of closed meshes) and master segment length
8 (total length of the network) of capillary tubes, in five random fields for each sample
9 and time of acquisition, were calculated using Angiogenesis Analyzer for ImageJ
10 software ¹³. Results for different experimental groups were expressed as mean \pm SD
11 from three independent experiments. Representative pictures at higher magnification
12 were also taken.
13
14
15
16
17
18
19
20
21
22
23
24

25 **2.8. Statistical analysis**

26
27 Data are presented as mean \pm SD of independent experiments. Comparisons were made
28 using Student's t-test or by ANOVA when appropriate. Values of $P < 0.05$ were
29 considered statistically significant. Statistical analysis was carried out using the Graph-
30 Pad Prism 5 software (GraphPad Software, Inc., La Jolla, CA 92037 USA).
31
32
33
34
35
36
37
38

39 **3. Results**

40 **3.1. Effect of Aminaphtone on cell viability**

41
42
43 To determine non-toxic concentration of AMNA, HUVECs were incubated in the
44 presence of different concentrations of drug (1–100 $\mu\text{g/ml}$). Dose-dependent HUVEC
45 viability indicated that no significant cytotoxic effects were observed at AMNA
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 concentrations below 30 $\mu\text{g/ml}$. At concentration up to 30 $\mu\text{g/ml}$ there was a rapid
6
7 reduction in cell viability, **Figure 1**.
8
9

10 11 **3.2. Effect of Aminaphtone on endothelial cell permeability**

12 The effect of different concentrations of AMNA on VEGF-induced HUVEC
13
14 permeability has been shown in **figure 2**. VEGF-induced cell permeability was
15
16 significantly reduced at a range concentration of 1-20 $\mu\text{g/ml}$ AMNA ($P < 0.05$ vs VEGF),
17
18 restoring normal condition. AMNA alone not affect cell permeability.
19
20
21
22
23
24

25 **3.3. VE-cadherin fluorescent detection**

26 To evaluate the effect of AMNA on VE-cadherin localisation, cells were fixed and
27
28 processed for immunofluorescence (**Figure 3**) As showed in figure, VE-cadherin was
29
30 localized as bright intense immunostaining at all cell-cell contacts (control and AMNA
31
32 treatment). VEGF stimulation for 2 h reduced the staining of VE-cadherin at cell-cell
33
34 contacts, that was now expressed in an irregular manner, and a loss of cell-cell
35
36 adhesions. On the contrary, AMNA pre-treatment restored VE-cadherin staining at cell-
37
38 cell contacts that was distributed in a striped fashion, like controls.
39
40
41
42
43
44

45 **3.4. VE-cadherin expression**

46 To correlate the immunolocalization changes with protein expression, Western blot
47
48 analysis of total VE-cadherin and phospho-VE-cadherin were performed (**Figure 4**).
49
50 Immunoblotting demonstrated that the levels of total VE-cadherin remained the same in
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 all treatment conditions. However, phosphoY685-VE-cadherin resulted reduced by
6
7 AMNA pre-treatment ($P<0.005$ vs VEGF) and increased by VEGF treatment ($P<0.001$
8
9 vs control), as confirmed by densitometry analysis. These data suggest a potential
10
11 protective role of AMNA on VE-cadherin degradation induced by VEGF.
12
13

14 15 16 **3.5. In vitro capillary tube maintenance**

17
18 HUVECs, when seeded on Matrigel, formed capillary-like structures. This process has a
19
20 rapid onset, beginning within 1 h and is completed by 8-12 h; after this time the network
21
22 starts to rearrange and completely disappears within 24-48 h.
23

24
25 **Figure 5** shows the effect of 10 $\mu\text{g/ml}$ AMNA 6h pre-treatment on capillary-like
26
27 structure maintenance, formed by HUVECs. In **figure 5 A**, AMNA significantly
28
29 reduced degradation of endothelial cells organised in endothelial cell cords on Matrigel
30
31 at 24 h and 48 h compared with control. **Figure 5 B**, shows the number of meshes and
32
33 master segment length of capillary tubes formed by HUVECs. After 48 h, there was a
34
35 significant difference in number of meshes and master segment length between control
36
37 and AMNA-treated cells ($P<0.01$).
38
39
40
41
42

43 **4. Discussion**

44
45 CVI is characterised by venous hypertension associated with decrease in
46
47 microcirculatory blood flow and increase in post-capillary permeability of the veins,
48
49 leading to oedema of the legs and feet ¹⁵. The most used phlebotropic drugs, or oedema-
50
51 protecting drugs, are the gamma-benzopyrone family (flavonoids) ¹⁶. Results of clinical
52
53
54
55
56
57
58
59
60

1
2
3
4
5 studies show that flavonoids decrease capillary permeability and increase capillary
6
7 resistance, which could partly be explained by inhibition of leukocyte activation,
8
9 migration, and adhesion ^{16,17}. As reported by Ramelet et al. (2000), this inhibition is
10
11 linked to a significant decrease in plasma levels of endothelial adhesion molecules
12
13 (VCAM-1 and ICAM-1) after flavonoids treatment ¹⁸. Beside the clinical outcome in
14
15 patients with CVI, AMNA has shown interesting endothelial-protective properties,
16
17 inducing down-regulation of sELAM-1 and sVCAM-1 in patients with systemic
18
19 sclerosis ¹⁹. Moreover, AMNA is a molecule with a demonstrated anti-endothelin1 (ET-
20
21 1) effect *in vitro*, interfering with the transcription of the pre-pro-ET-1 (PPET-1) gene
22
23 ²⁰. Furthermore, ET-1 is known to acts as a permeability factor in the vascular
24
25 endothelium ²¹⁻²³. It is known that HUVECs treated with VEGF increased their ET-1
26
27 production in a concentration and time-dependent manner ²⁴. In addition, Chen et al.
28
29 (2000), demonstrated that VEGF increased both ET-1 mRNA and ET-1 protein
30
31 expression along with endothelial cell permeability in HUVECs cultured in normal
32
33 glucose condition. Interestingly, they reported that ET-1 induces a disruption of the
34
35 endothelial cell junctions ²⁵. Moreover, in a recent work, we demonstrated that AMNA
36
37 reduced significantly ET-1 secretion in HUVECs ²⁶.

38
39
40
41
42
43 In this study, AMNA was able to restore vascular permeability induced by VEGF in a
44
45 concentration range of 1-20 µg/ml. Inhibition of VE-cadherin function induces a
46
47 reorganisation of the actin cytoskeleton leading to a loss of junctional VE-cadherin
48
49 localization, reduces cell-cell adhesion and increases permeability ²⁷. It is know that
50
51 VEGF stimulation reduces VE-cadherin staining at the adherent junction ^{7, 27-29}.

52
53
54
55
56
57
58
59
60

1
2
3
4
5 Moreover, it is generally accepted that the tyrosine phosphorylation of VE-cadherin is
6 associated with weak junctions and impaired barrier function. In particular, it has been
7 proved that VEGF enhance the permeability of HUVEC monolayers and increase
8 tyrosine phosphorylation of VE-cadherin ³⁰. In our study, AMNA pre-treatment restored
9 VE-cadherin localization at the cell-cell contacts. In addition, protein expression of total
10 VE-cadherin remained the same in all treatment conditions, whereas phospho-tyrosin
11 685-VE-cadherin resulted increased by VEGF treatment (compared to control) and
12 reduced by AMNA pre-treatment.
13
14

15
16
17
18
19
20
21
22 Finally, HUVECs, when seeded on Matrigel, formed capillary-like structures. This
23 process has a rapid onset, beginning within 1 h and is completed by 8-12 h; after this
24 time the network starts to rearrange and completely disappears within 24-48 h. We used
25 Matrigel assay to evaluate the effect of AMNA pre-treatment on degradation time of
26 capillary-like structures formed by HUVECs. In accordance with the role of VE-
27 cadherin in both formation and maintenance of capillary tubes in fibrin collagen gel-
28 over-gel assays ⁷, our data showed that AMNA improved stability of endothelial cells
29 organised in capillary-like structures, as observed after 48 h.
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **4.1. Limitations and future directions**

44
45 One potential limitation of this study was the completely absences of *in vitro* studies on
46 the mechanism of action of AMNA and its intracellular pathway involved. Here, for the
47 first time, the influence of AMNA on VE-cadherin modulation was suggested.
48
49

50 Moreover, we lack of clinical experience of oedema reduction.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Future direction may be an *in vitro* study on endothelial cells cultured from veins of
6
7 patients with CVI to set up a personalized study. Finally, a multicentric clinical studies
8
9 would be essential to confirm the effect of AMNA on oedema reduction mainly in leg
10
11 ulcer.
12
13

14 15 16 **4.2. Conclusion**

17
18 AMNA is used to reduce lower limbs oedema in chronic venous insufficiency.

19
20 On the basis of our experience, we can suppose that the effect of AMNA is due to
21
22 protection of VE-cadherin degradation induced by VEGF and to its effect on ET-1
23
24 expression. These properties of AMNA may also explain the stability of endothelial
25
26 cells organised in extracellular matrix.
27
28
29
30
31

32 **Disclosures**

33
34 The authors declare no conflicts of interest.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Nagy JA, Benjamin L, Zeng H, et al. Vascular permeability, vascular hyperpermeability and angiogenesis. *Angiogenesis* 2008; 11: 109-119.
2. Wu MH, Yuan SY and Granger HJ. The protein kinase MEK1/2 mediate vascular endothelial growth factor- and histamine-induced hyperpermeability in porcine coronary venules. *J Physiol* 2005; 563: 95-104.
3. Parsons JT, Horwitz AR and Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. *Nat Rev Mol Cell Biol* 2010; 11: 633-643.
4. Kelly M, Hwang JM and Kubes P. Modulating leukocyte recruitment in inflammation. *J Allergy Clin Immunol* 2007; 120: 3-10.
5. Dejana E and Del Maschio A. Molecular organization and functional regulation of cell to cell junctions in the endothelium. *Thromb Haemost* 1995; 74: 309-312.
6. Lampugnani MG and Dejana E. Interendothelial junctions: structure, signalling and functional roles. *Curr Opin Cell Biol* 1997; 9: 674-682.
7. Bach TL, Barsigian C, Chalupowicz DG, et al. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. *Exp Cell Res* 1998; 238: 324-334.
8. Bach TL, Barsigian C, Yaen CH, et al. Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. *J Biol Chem* 1998; 273: 30719-30728.
9. Hordijk PL, Anthony E, Mul FP, et al. Vascular-endothelial-cadherin modulates endothelial monolayer permeability. *J Cell Sci* 1999; 112 (Pt 12): 1915-1923.

10. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, et al. Phlebotonics for venous insufficiency. *Cochrane Database Syst Rev* 2016; 4: CD003229.
11. De Anna D, Mari F, Intini S, et al. [Effects of therapy with aminaftone on chronic venous and lymphatic stasis]. *Minerva Cardioangiol* 1989; 37: 251-254.
12. Pereira de Godoy JM. Aminaphtone in idiopathic cyclic oedema syndrome. *Phlebology* 2008; 23: 118-119.
13. Belczak SQ, Sincos IR, Campos W, et al. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. *Phlebology* 2014; 29: 454-460.
14. Chowdhury ZA, Barsigian C, Chalupowicz GD, et al. Colocalization of tissue transglutaminase and stress fibers in human vascular smooth muscle cells and human umbilical vein endothelial cells. *Exp Cell Res* 1997; 231: 38-49.
15. Nicolaidis AN. Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). *Circulation* 2000; 102: E126-163.
16. Eberhardt RT and Raffetto JD. Chronic venous insufficiency. *Circulation* 2014; 130: 333-346.
17. Gulati OP. Pycnogenol(R) in chronic venous insufficiency and related venous disorders. *Phytother Res* 2014; 28: 348-362.
18. Ramelet AA. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema. *Angiology* 2000; 51: 19-23.

- 1
2
3
4
5 19. Scorza R, Santaniello A, Salazar G, et al. Effects of aminafone 75 mg TID on
6 soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients
7 with systemic sclerosis. *Clin Ther* 2008; 30: 924-929.
8
- 9
10
11 20. Scorza R, Santaniello A, Salazar G, et al. Aminafone, a derivative of 4-
12 aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in
13 vitro Study. *Drugs R D* 2008; 9: 251-257.
14
15
- 16
17
18 21. Levin ER. Endothelins. *N Engl J Med* 1995; 333: 356-363.
19
- 20
21 22. Vanhoutte PM. Endothelin-1. A matter of life and breath. *Nature* 1994; 368:
22 693-694.
23
- 24
25 23. Victorino GP, Newton CR and Curran B. Endothelin-1 decreases microvessel
26 permeability after endothelial activation. *J Trauma* 2004; 56: 832-836.
27
- 28
29 24. Lee KJ, Kim MK, Park YH, et al. Vascular endothelial growth factor induces
30 endothelin-1 production via matrix metalloproteinase-2 rather than endothelin-
31 converting enzyme-1. *Hypertens Pregnancy* 2007; 26: 189-199.
32
33
- 34
35 25. Chen S, Apostolova MD, Cherian MG, et al. Interaction of endothelin-1 with
36 vasoactive factors in mediating glucose-induced increased permeability in endothelial
37 cells. *Lab Invest* 2000; 80: 1311-1321.
38
39
- 40
41
42 26. Frullini A, Da Pozzo E, Felice F, et al. Prevention of excessive endothelin-1
43 release in sclerotherapy: in vitro and in vivo studies. *Dermatol Surg* 2014; 40: 769-775.
44
45
- 46
47 27. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis.
48
49
50 *Nat Rev Mol Cell Biol* 2005; 6: 622-634.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5 28. Gavard J and Gutkind JS. VEGF controls endothelial-cell permeability by
6 promoting the beta-arrestin-dependent endocytosis of VE-cadherin. *Nat Cell Biol* 2006;
7 8: 1223-1234.
8
9
10
11 29. Yamaoka-Tojo M, Tojo T, Kim HW, et al. IQGAP1 mediates VE-cadherin-
12 based cell-cell contacts and VEGF signaling at adherence junctions linked to
13 angiogenesis. *Arterioscler Thromb Vasc Biol* 2006; 26: 1991-1997.
14
15
16 30. Esser S, Lampugnani MG, Corada M, et al. Vascular endothelial growth factor
17 induces VE-cadherin tyrosine phosphorylation in endothelial cells. *J Cell Sci* 1998; 111
18 (Pt 13): 1853-1865.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Under Review




Figure 1. Dose-dependent effect of AMNA on cell viability. HUVECs were treated with different concentration of AMNA (1 – 5 – 10 – 30 – 50 – 70 – 100 µg/ml) for 6 h. Cell viability was evaluated by WST-1 colorimetric assay (Abs 450 nm). Data are expressed as percentage of control of 3 independent experiments \pm SD.

53x32mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Permeability of HUVEC monolayers to FITC-dextran. Cells were grown to confluency on Transwell filters and pre-treated with different concentrations of AMNA (0.5 – 1 – 5 – 10 – 20 µg/ml) for 6h and then with or without VEGF (50 ng/ml) for 2h. Permeability was measured using FITC-dextran (MW 70 KDa) as described in Materials and Methods. Data are expressed as percentage of FITC-dextran diffusion of empty filter (no cells) and are representative of three independent experiments. Ex 485 nm; Em 538 nm. **P < 0.05 vs VEGF.

86x52mm (600 x 600 DPI)

View




Figure 3. VE-cadherin localization in HUVECs. Confluent cell monolayers were pre-treated with AMNA (10 $\mu\text{g/ml}$) for 6 h and with VEGF (50 ng/ml) for 2 h. Cells were immunostained for VE-cadherin (green) and F-actin (red). Cell nuclei were counterstained with DAPI (blue). All fluorescence images were taken at five different fields/well, and images are representative of three independent experiments (magnification 20X).

44x10mm (300 x 300 DPI)

Under Review





Figure 4. VE-cadherin expression. HUVECs were cultured until confluences and pre-treated with 10 μ g/ml AMNA for 6 h and then with 50 ng/ml VEGF for 2 h in medium with 1 % FBS. Western blot analysis of cell lysate was performed. Anti-VE Cadherin (phospho-Y685) at 140 kDa and anti-VE-cadherin antibody at 147 kDa were detected. Quantitative analysis has been normalized to beta-actin (as control). Samples derive from the same experiment and the gels and blots were processed in parallel. ** $P < 0.005$ vs VEGF and § $P < 0.001$ vs control.

147x155mm (600 x 600 DPI)




Figure 5. Capillary-like structures maintenance. Cells were treated for 6 h with 10 µg/ml AMNA and then 7x10⁴ cells/well were plated on Matrigel for 48 h. Images were acquired after 2-8-24-48 h. Images are representative of 5 random-field (original magnification 5X) (A). Optical microscope images were analysed through Angiogenesis Analyzer for ImageJ software to measure number of meshes and master segment length of capillary tubes formed by HUVECs after 2-8-24-48 h (B). Five random fields for each sample and time of acquisition were analysed. Values in the graph are the mean from three independent experiments ± SD. **P<0.01 vs control.

137x99mm (300 x 300 DPI)

1
2
3 **Declarations**
4

5
6 **Competing interests:** The Authors declares that there is no conflict of interest
7

8
9 **Funding:** This research received no specific grant from any funding agency in the public,
10 commercial, or not-for-profit sectors.
11

12
13
14 **Ethical approval:** NA
15

16
17 **Guarantor:** RD
18

19
20 **Contributorship:** FF and RD researched literature, wrote and conceived the study. EB was
21 involved in protocol development, acquisition and analysis of data. TS and EI revised critically the
22 manuscript for important intellectual content. AF and RD approved the version to be published. All
23 authors reviewed and edited the manuscript and approved the final version of the manuscript.
24
25
26
27
28

29
30 **Acknowledgements:** NA
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

review